Dr. Nolan Priedigkeit

Nolan Priedigkeit, MD, PhD is a medical oncologist at Dana-Farber Cancer Institute (DFCI) and Instructor of Medicine at Harvard Medical School. Clinically, he specializes in breast cancer and his research aims to merge computational and genomic sciences with technology development to make an impact on how we understand and treat metastatic disease. He received dual MD/PhD degrees from the University of Pittsburgh-Carnegie Mellon University Medical Scientist Training Program where his thesis applied translational genomics to discover novel drug targets in advanced breast cancers. He completed an internal medicine residency at Brigham & Women’s Hospital, a medical oncology fellowship at Dana-Farber/Mass General Brigham, and currently leads multidisciplinary research projects at the Broad Institute of MIT & Harvard focused exclusively on breast cancer. He has been supported by awards from the National Cancer Institute, American Association for Cancer Research, Conquer Cancer Foundation of ASCO, Lubin Family Foundation, and the Susan G. Komen Foundation. He values patient-centered care with a focus on open and transparent communication, generous sharing of research data and ideas, as well as mentorship of trainees in both science and medicine.

Dr. Priedigkeit is highly rated in 3 conditions, according to our data. His clinical expertise encompasses Breast Cancer, Inflammatory Breast Cancer, PIK3CA-Related Overgrowth Spectrum, and Metastatic Brain Tumor.

Dr. Priedigkeit is board certified in Internal Medicine. He is actively involved in clinical research, co-authoring 31 peer reviewed articles.